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Introduction
Patients with systemic lupus erythematosus (SLE), can
produce antibodies directed against the complex phos-
pholipds-b-glycoprotein 1. Rituximab is an antibody
directed to most B-cells, except precursors and mature
plasma cells. It can produce reductions in antibody titers.
We have treated SLE patients refractory to conventional
immunosuppressive therapy, with Rituximab and we
searched for a reduction in anticardiolipin autoantibodies.
Material and methods
We have performed an observational, retrospective and
multicentric study from 3 Spanish hospitals. We ana-
lysed 46 patients with complex clinical index (SLEDAI,
physician global assessment scale) and laboratory deter-
minations, included anticardiolipin levels, at start, week
24 and final visit.
Results
W eh a v et r e a t e d4 6p a t i e n t s ,3m e na n d4 3w o m e n ,
91.3% Caucasians. Antiphospholipid syndrome was pre-
sent in 14 patients (30.4%). A Lupus Anticoagulant (LA)
was detected in 42.9%.
40 patients received the dose for arthritis (2x1g) and
4x375mg/m2 in the others. The mean of cycles used
was 2 (1-3).
After the Rituximab therapy the LA was positive in
only 10% (p<0.05). Anticardiolipin levels were reduced
too, IgG aCL showed a significant reduction from 8.57
UI (3.44, 53.20) to 5.93 UI (1.70, 40.50), p<0.002. A non
significant reduction in IgM aCL was detected 4.61 UI
(2, 19.6) to 2.75 (1.02, 6.3). We have not detected new
thrombotic events after Rituximab therapy.
Discussion
We have observed a reduction in the anticardiolipin
antibody titers and LA among SLE patients treated with
Rituximab. No new thrombotic episodes were observed
after treatment with a mean follow-up of 21.1 months.
We think may be necessary a longer follow-up to decide
a possible efficacy for Rituximab in the management or
antiophospholipid syndrome.
In spite of the absence of significant improvement of
patient in the EXPLORE study, an analysis by Tew,
shows a reduction of anticardiolipin antibodies levels to
near normal. A bibliographic search for similar studies
has not yield other results.
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